Press & News
We’re pushing boundaries and making news
-
Apr 10
2023Babson Diagnostics Welcomes New Clinical Advisor, Andrew Carroll, M.D.
We're adding key clinical expertise as we move closer to commercialization of our next-generation blood testing ecosystem.
-
Mar 28
2023Babson Diagnostics and ClosedLoop Team Selected as 1st Place Winner of ‘Help with Hemolysis’ Data Analytics Challenge
Competition co-hosted by Washington University and American Association for Clinical Chemistry challenges participants to solve real-world clinical laboratory challenges using data science.
-
Mar 08
2023Babson Diagnostics Celebrates International Women's Day
Making meaningful progress to close the STEM Gap.
-
Feb 02
2023Babson Diagnostics Unveils Brand Identity for Next-Generation Blood Testing
The new name of our diagnostic blood testing service is designed around the most important element of testing – the customer.
-
Nov 21
2022Validating Our Blood Testing Innovations
What do we mean when we say we're a "science-first" company?
-
Sep 20
2022Babson Diagnostics Welcomes Four New Leaders to Management Team
Key expertise added as Babson works to commercialize its reimagined blood testing ecosystem.
-
Sep 07
2022Preventative Healthcare Access for All Patients
Better outcomes start with meeting patients where they are.
-
Jul 26
2022Babson Diagnostics and Pharmacy Podcast Network Announce Partnership That Will Take Listeners Inside Largest Retail Pharmacy Trade Show
Media partnership announced in connection with the 2022 National Association of Chain Drug Stores' Total Store Expo.
-
Jun 13
2022Medical Claims Data Underscores Need to Improve Lab-Testing Access and Action
Claims data underscores need to improve preventative care.
-
Jun 07
2022Why Innovation in Blood Testing Matters
When people think about innovations that can reshape health care, why don’t they usually think about blood testing?
-
May 11
2022Babson Diagnostics, BD Expand Strategic Partnership to Advance Diagnostic Blood Collection in New Care Settings
Expanded collaboration agreement to make less invasive blood sample collection more convenient and patient centered.
-
Mar 21
2022How Do We Fill The Data Gap In Virtual Care?
Babson Diagnostics CEO David Stein details how can patients and providers get the most from virtual care.
-
Mar 17
2022Babson Diagnostics Recognized for Achieving Highest Standards for Laboratory Medicine
Babson awarded accreditation by CAP for meeting the highest standards of quality and patient safety in lab practices.
-
Jan 19
2022Babson Diagnostics Grows Leadership Team with Key Executive Hires
Healthtech firm prepares for commercial launch of disruptive blood-testing ecosystem.
-
Jan 04
2022Health Tech Needs to Rebuild Trust in the Wake of the Theranos Verdict
Babson Diagnostics CEO David Stein shares some ideas about how we as an industry move forward from the Theranos scandal.
-
Nov 12
2021Raising Diabetes Awareness Starts with Testing
With November being National Diabetes Month, it’s a good time to take stock of the toll this disease takes on our country.
-
Oct 15
2021Pharmacies and the Future of Health Care
Use of COVID-19 testing and vaccination services at community pharmacies demonstrates they can play a bigger role in care delivery.
-
Jul 27
2021Babson Diagnostics Strengthens Senior Leadership Team with Two Appointments
Babson brings in top talent from the largest and most respected retail and health care services organizations in the country.
-
Jun 29
2021Babson Diagnostics Raises $31 Million in Series B Funding to Drive Retailization of Customer-First, Convenient, and Highly Accessible Diagnostic Blood Testing
The Series B fundraise will accelerate the commercialization of Babson’s disruptive technology that will make routine blood testing easier, more accessible, and less invasive.
-
May 04
2021Time for Innovation in Blood Testing Technology
We live in a just-in-time world. We only need to pick up our smartphones and within moments we order a car to drive us home. Or book a reservation at a hotel or restaurant.
-
Mar 09
2021Babson Diagnostics Named Fierce MedTech "Fierce 15" Company
Babson named one of Fierce Medtech’s elite “Fierce 15" as a promising private company in the global health care industry.
-
Jan 25
2021Babson Diagnostics First to Conduct Full Blood Panel Testing from a Finger Sample in a Retail Setting
According to the CDC, 70% of today’s medical decisions depend on laboratory test results, and over 14 billion laboratory tests are ordered annually—but primary care clinicians indicate up to 30% of prescribed diagnostic tests are not filled by patients.
-
Sep 24
2020Babson Diagnostics Appoints Former Siemens Healthineers Executive to CEO
Babson has appointed David Stein, Ph.D., former head of global strategy and innovation at Siemens Healthineers, to chief executive officer. Eric Olson, Babson’s founder and former CEO, will assume the roles of chairman of the board and chief operating officer.
-
Sep 24
2020Babson Diagnostics Closes $13.7 Million Series A to Democratize Diagnostic Blood Testing
Babson announced today it closed $13.7 million in cumulative Series A funding, led by Siemens Healthineers, Prism Ventures, Genesis Merchant Capital, and Lago Consulting Group.
-
Jun 25
2020Babson Diagnostics Receives FDA Emergency Use Authorization for its SARS-CoV-2 IgG Antibody Test
Babson announced today that its SARS-CoV-2 IgG antibody test, Babson Diagnostics aC19G1, has received emergency use authorization (EUA) from the Food and Drug Administration (FDA).
-
May 20
2020Babson Diagnostics Enters Collaborative Research Agreement with Dell Medical School to Study Immune Response to COVID-19
Babson announced today it has entered into a collaborative research agreement with Dell Medical School at The University of Texas at Austin (Dell Med) to study the immune response to COVID-19.
-
Apr 30
2020Babson Diagnostics Launches COVID-19 Serology Test for IgG Antibodies with 100% Specificity in Austin
Babson announces launch of its first COVID-19 serology test to detect IgG antibodies to SARS-CoV-2 in the bloodstream through a select network of retail and clinical partners in Austin, Texas.
-
Apr 15
2020Babson Diagnostics to Offer High-Throughput COVID-19 Serology Testing in Austin, Texas
Babson announces it will launch a COVID-19 serology testing service to detect the presence of antibodies to SARS-CoV-2 in the bloodstream.
-
Mar 11
2020Babson Diagnostics Bolsters Board of Directors with Three Diagnostics Industry Experts
Babson announces that it has expanded its board of directors to include diagnostics industry leaders David Stein (Director), Dennis Gilbert (Director), and Dave Hickey (Observer).
-
Feb 12
2020BD, Babson Diagnostics Announce Strategic Partnership Agreement to Enable Small-Volume Blood Collection for Diagnostic Testing in Retail Settings
BD and Babson Diagnostics announce a long-term strategic partnership agreement to bring laboratory-quality, small-volume blood collection to retail pharmacies.
-
Jul 30
2019Babson Diagnostics announces its Scientific Advisory Board
Babson has established its Scientific Advisory Board. Drs. Alan Wu, Susan A. Evans, and Robert H. Christenson will join the Babson team as scientific advisors.
-
May 23
2019Babson Diagnostics Wins Austin A-List Award
Babson named a winner at the Greater Austin Chamber of Commerce’s 2019 Austin A-List Awards, “Austin’s premiere honor for homegrown companies.”
-
May 14
2019Babson Diagnostics welcomes Mini Kahlon to its Board of Directors
Babson welcomes Mini Kahlon as the newest member of its Board of Directors.
-
Mar 11
2019Babson Diagnostics featured in Capital City Innovation Annual Report
Babson featured in Capital City Innovation's 2018 Annual Review. Capital City Innovation is a 501(c)(3) nonprofit focused on cultivating collaboration and growth in Austin's Innovation District.
-
Oct 19
2018Babson Diagnostics secures $3.5 million in Series A financing from Prism Ventures
Babson secures $3.5 million in Series A financing on October 4 from Prism Ventures, a New York-based advisory and investment firm specializing in life sciences.
Media contact
For PR and media inquiries, please reach out to pr@babsondx.com.